Grenoble Alps University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Grenoble France (1339)

Organization Overview

First Clinical Trial
2013
NCT03598582
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centre hospitalier universitaire grenoble alpes | CHU de Grenoble | CHU de Grenoble - La Tronche - Hôpital A. Michallon, France | CHU Grenoble Alpes | CHU Grenoble Alpes, Grenoble Alpes University | Clinical pharmacology unit, grenoble alpes university hospital | EFCR Department and Sleep Laboratory, Grenoble Alpes University Hospital | Grenoble Alpes University Hospital | Grenoble Alpes University Hospital (CHUGA) | Grenoble - CHU | Grenoble University Hospital, Clinical Pharmacology Department | IDEX - Univ. Grenoble-Alpes | Laboratoire SENS, Univ. Grenoble-Alpes | Métropole Grenoble-Alpes | UniversitéGrenobleAlpes | Université Grenoble Alpes | Université Grenoble-Alpes | Université Grenoble Alpes, LIP/PC2S, EA 4145, Grenoble

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cardiovascular Diseases (Phase 2)

Coronary Artery Disease (Phase 2)

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Hemorrhage (Phase 3)

Ischemia (Phase 2)

Lung Neoplasms (Phase 2)

Myelodysplastic Syndromes (Phase 4)

Myocardial Ischemia (Phase 2)

Preleukemia (Phase 4)

Prostatic Neoplasms (Phase 3)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Shock, Hemorrhagic (Phase 3)

Skin Ulcer (Phase 2)

Syndrome (Phase 4)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 12